Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27618726 | 0.88 | ALDH1A1 (0.42) | GPR35 | |
| SCHEMBL13616451 | 0.86 | — | — | |
| SCHEMBL16769654 | 0.83 | MRGPRX4 (0.40) | MEN1KMT2AGPR35MMP2 | |
| SCHEMBL29259916 | 0.82 | RXRA (0.40) | EPAS1 | |
| SCHEMBL18573171 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL195665 | 0.79 | SLC6A2 (0.43) | EPAS1 | |
| SCHEMBL28184291 | 0.77 | CYP1A1 (0.30) | — | |
| SCHEMBL195649 | 0.77 | CA2 (0.48) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL12711287 | 0.72 | PARP15 (0.53) | KCNH2MEN1KMT2ACA1CA2 | |
| SCHEMBL12841314 | 0.72 | MMP2 (0.51) | MEN1KMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076592-A | SHP2 inhibitor, pharmaceutical composition comprising same and use thereof | 北京泰德制药股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-9128238-B2 | Optical material and molded product thereof | MITSUI CHEMICALS, INC. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20130030136-A1 | OPTICAL MATERIAL AND MOLDED PRODUCT THEREOF | MITSUI CHEMICALS, INC. (JP) | 2013-01-31 | — | — | US | disclosed |
| US-7659416-B2 | Monomolecular conductive complex, conductive self-assembled film and assembly of electrode composed of metal and semiconductor making use of the same | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090036698-A1 | Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same | TOKYO INSTITUTE OF TECHNOLOGY | 2009-02-05 | — | — | US | disclosed |
| EP-1862453-A1 | MONOMOLECULAR CONDUCTIVE COMPLEX, CONDUCTIVE SELF-ASSEMBLED FILM AND ASSEMBLY OF ELECTRODE COMPOSED OF METAL AND SEMICONDUCTOR MAKING USE OF THE SAME | Tokyo Institute of Technology (JP) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036698-A1 | Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same | CNTN1, GAP43, AP3M1 | VCAM1 1600/4885KCNH2 85/4885TTR 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.